Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
Researchers sought to determine whether combining imatinib with ISR inhibition would improve leukemic cell eradication in CML.
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
Researchers sought to determine whether combining dasatinib and Peg-IFN-alpha2b would be an effective treatment for patients with newly diagnosed CML.
Researchers sought to determine whether asciminib would be superior to bosutinib in patients with chronic myeloid leukemia in chronic phase.
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
Researchers sought to determine whether treatment with FLAG-IDA could induce a second chronic phase in patients with CML.
Researchers sought to determine whether asciminib would be better than bosutinib for treating patients with chronic myeloid leukemia in chronic phase.
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?